GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Luye Pharma Group 2186.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

1.67

-0.60%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥7.35bn

FY2016FY2025

Net income

CN¥720.9m

FY2016FY2025

Free cash flow

CN¥909.3m

FY2016FY2025

Shareholders' equity

CN¥18.73bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥7.35bnCN¥7.06bnCN¥7.16bnCN¥6.97bnCN¥6.06bnCN¥6.45bnCN¥7.41bnCN¥6.03bnCN¥4.44bnCN¥3.40bn
Gross profitCN¥4.85bnCN¥4.71bnCN¥4.90bnCN¥4.82bnCN¥3.96bnCN¥4.65bnCN¥5.68bnCN¥4.72bnCN¥3.45bnCN¥2.78bn
Research and developmentCN¥482.3mCN¥580.9mCN¥682.9mCN¥998.9mCN¥796.0mCN¥920.3mCN¥675.1mCN¥572.3mCN¥336.4mCN¥225.6m
Operating incomeCN¥1.42bnCN¥1.31bnCN¥1.07bnCN¥1.03bnCN¥510.3mCN¥1.55bnCN¥2.32bnCN¥1.77bnCN¥1.28bnCN¥1.40bn
Net incomeCN¥720.9mCN¥549.8mCN¥620.6mCN¥704.7m−CN¥156.6mCN¥823.3mCN¥1.71bnCN¥1.52bnCN¥1.14bnCN¥1.04bn
Diluted earnings per share0.180.150.160.20-0.050.260.540.470.350.31

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥38.26bnCN¥34.50bnCN¥29.70bnCN¥28.25bnCN¥26.31bnCN¥24.04bnCN¥22.50bnCN¥20.43bnCN¥12.54bnCN¥10.73bn
Cash and short-term investmentsCN¥10.35bnCN¥7.58bnCN¥7.11bnCN¥6.46bnCN¥6.42bnCN¥6.30bnCN¥6.05bnCN¥5.67bnCN¥4.48bnCN¥3.20bn
Total liabilitiesCN¥16.54bnCN¥16.15bnCN¥13.94bnCN¥15.39bnCN¥15.69bnCN¥14.60bnCN¥11.58bnCN¥11.19bnCN¥4.50bnCN¥3.08bn
DebtCN¥12.06bnCN¥10.51bnCN¥8.76bnCN¥9.25bnCN¥9.74bnCN¥10.14bnCN¥8.65bnCN¥6.22bnCN¥2.88bnCN¥1.62bn
Shareholders' equityCN¥18.73bnCN¥16.49bnCN¥14.60bnCN¥11.86bnCN¥9.89bnCN¥9.19bnCN¥10.29bnCN¥9.10bnCN¥7.89bnCN¥7.49bn
Shares outstanding4,030m3,762m3,762m3,484m3,476m3,137m3,157m3,223m3,236m3,321m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥2.08bnCN¥195.5mCN¥1.86bnCN¥1.93bnCN¥212.5mCN¥1.20bnCN¥2.03bnCN¥1.22bnCN¥1.12bnCN¥689.8m
Capital spending−CN¥1.17bn−CN¥1.99bn−CN¥1.36bn−CN¥1.36bn−CN¥1.80bn−CN¥1.77bn−CN¥3.76bn−CN¥2.89bn−CN¥728.4m−CN¥371.8m
Free cash flowCN¥909.3m−CN¥1.80bnCN¥501.3mCN¥571.1m−CN¥1.58bn−CN¥566.8m−CN¥1.72bn−CN¥1.68bnCN¥394.9mCN¥317.9m
Dividends paid—————−CN¥204.5m−CN¥439.0m−CN¥337.6m−CN¥247.7m−CN¥124.6m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥3.45bnCN¥3.64bnCN¥3.71bnCN¥3.48bnCN¥3.58bnCN¥3.77bnCN¥3.38bnCN¥3.65bn
Gross profitCN¥2.19bnCN¥2.34bnCN¥2.51bnCN¥2.29bnCN¥2.42bnCN¥2.63bnCN¥2.26bnCN¥2.44bn
Operating incomeCN¥892.9mCN¥714.2mCN¥733.9mCN¥570.5mCN¥766.2mCN¥794.9mCN¥241.3mCN¥398.6m
Net incomeCN¥448.7mCN¥356.4mCN¥364.6mCN¥97.9mCN¥451.9mCN¥445.8mCN¥174.7mCN¥358.6m
Diluted earnings per share0.110.090.090.030.120.120.050.10
Cash from operations—CN¥406.0mCN¥2.07bnCN¥654.0m−CN¥459.0mCN¥1.05bnCN¥803.0mCN¥1.22bn
Capital spending—−CN¥74.0m−CN¥735.0m−CN¥692.0m−CN¥903.0m−CN¥737.0m−CN¥1.27bn−CN¥763.0m
Free cash flow—CN¥332.0mCN¥1.33bn−CN¥38.0m−CN¥1.36bnCN¥318.0m−CN¥465.0mCN¥459.0m
Total assetsCN¥40.63bnCN¥38.26bnCN¥37.32bnCN¥34.50bnCN¥31.69bnCN¥29.70bnCN¥30.64bnCN¥28.25bn
Cash and short-term investmentsCN¥15.53bnCN¥10.35bnCN¥10.29bnCN¥7.58bnCN¥7.55bnCN¥7.11bnCN¥9.21bnCN¥6.46bn
DebtCN¥11.30bnCN¥12.06bnCN¥13.83bnCN¥12.03bnCN¥11.01bnCN¥9.81bnCN¥11.50bnCN¥10.61bn
Shareholders' equityCN¥18.15bnCN¥18.73bnCN¥17.12bnCN¥16.49bnCN¥15.17bnCN¥14.60bnCN¥13.21bnCN¥11.86bn

Financial ratios

Data as of 7 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin66.0%66.7%68.4%69.2%65.3%72.0%
Operating margin19.3%18.6%22.4%19.1%6.2%24.7%
Net margin9.8%7.8%8.7%10.1%-2.6%12.8%
Return on equity3.8%3.3%4.3%5.9%-1.6%9.0%
Return on assets1.9%1.6%2.1%2.5%-0.6%3.4%
Free cash flow yield38.6%27.9%41.0%45.2%27.7%45.5%
Revenue growth4.1%-1.3%2.7%15.0%-6.1%-12.9%
Earnings growth31.1%-11.4%-11.9%-550.0%-119.0%-51.9%
Current ratio1.53x1.24x1.32x1.14x1.42x1.38x
Debt to equity0.64x0.73x0.67x0.89x1.12x1.26x
Equity ratio49.0%47.8%49.2%42.0%37.6%38.3%
Interest coverage1.77x2.01x2.04x2.42x0.81x3.22x
R&D as a share of sales6.6%8.2%9.5%14.3%13.1%14.3%
Buybacks as a share of market value-7.1%0.0%-8.0%-0.2%-10.8%0.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue1.8%2.6%9.4%
Operating income11.4%-1.7%1.0%
Net income0.8%-2.6%-2.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin66.3%67.6%67.9%71.9%
Operating margin19.0%16.9%16.8%22.9%
Net margin8.8%9.1%7.9%14.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings13.312.919.615.7-68.511.89.310.015.112.7
Price to sales1.31.01.71.61.81.52.12.53.93.9

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 29 Jun 2020.

FY2020FY2019FY2018FY2017FY2016
Paid in the year0.060.1320.1050.0720.037

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.